Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-16269110 dose-ranging study in overweight and obese adults
NL-OMON30928Phase 2Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of usistapide in obesity and Overweight (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Mean change in body weight from baseline to Week 12. Planned start Oct 2007; status: not yet recruiting.
02
Drugs
usistapide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NL-OMON30928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30928.